• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

abbott

FDA clears Abbott’s iPhone app for FreeStyle Libre 2

August 2, 2021 By Sean Whooley

Abbott logo updated

Abbott (NYSE:ABT) announced today that it received FDA clearance for its FreeStyle Libre 2 iOS application for use with compatible iPhones. The Abbott Park, Ill.-based company designed the new FreeStyle Libre 2 app to enable users to get glucose readings directly on their iPhones without the use of a reader, allowing caregivers to remotely monitor […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott

Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent

August 2, 2021 By Sean Whooley

Abbott Xience Skypoint

Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform. When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs for its vascular business Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation. As a practicing interventional cardiologist, West […]

Filed Under: Auto-injectors, Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Pharmaceuticals, Regulatory/Compliance, Vascular Tagged With: abbott, drug-eluting balloons, drug-eluting stents, FDA

Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system

May 10, 2021 By Sean Whooley

Bigfoot Biomedical smart insulin pen cap

Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system. Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release. Bigfoot Unity smart pen caps offer on-demand […]

Filed Under: Auto-injectors, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: abbott, Bigfoot Biomedical, Eli Lilly & Co., Novo Nordisk, sanofi

How CGM tech has advanced in the 21st century

March 11, 2021 By Brian Buntz

CGMs Diabetes 21st Century Dexcom Medtronic Abbott Senseonics

The rapid evolution of the continuous glucose monitor (CGM) has brought flexibility and convenience to diabetes control. Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Efforts to manage glucose kicked off in earnest when researchers began measuring glucose in […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Diabetes, Diagnostics, Drug-Device Combinations, Featured Tagged With: abbott, CGM, Dexcom, Medtronic, Senseonics

Global wearable patch market growing at 10.6% rate

February 22, 2021 By Sean Whooley

G6

Researchers say that the global wearable patch market size is expected to reach $12.6 billion by 2026, marking a massive rise over five years. According to the research, put together by ResearchAndMarkets.com, the rise is expected to represent a compound annual growth rate of 10.6% during the forecast period. Wearables covered by the research, including […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: abbott, Dexcom, Eli Lilly & Co., Insulet, sanofi, wearables

Looking back at two decades of CGM advances

February 10, 2021 By Brian Buntz

FreeStyle Libre 2 from Abbott

Continuous glucose monitors (CGMs) have transformed how many people with diabetes manage blood sugar, but attempts to monitor blood glucose have a long history. Attempts to manage glucose kicked off in earnest when researchers began measuring glucose in urine in the mid-1800s. Scientists’ ability to do so steadily improved over the years, but urine glucose […]

Filed Under: Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), mHealth (Mobile Health) Tagged With: abbott, DexCom Inc., diabetes management, digital health, Eversense, FDA, Medtronic, mhealth, Senseonics

Canada approves Abbott Freestyle Libre 2 for adults and children

December 3, 2020 By Sean Whooley

Abbott (NYSE:ABT) announced that Health Canada has approved its FreeStyle Libre 2 continuous glucose monitor for adults and children. The next-generation, wearable, sensor-based CGM technology with real-time alarms is approved for use in adults and children (four years old and up) and will be priced the same as the current FreeStyle Libre system, according to a […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Regulatory/Compliance Tagged With: abbott, Health Canada

Abbott touts Xience DES study results

October 15, 2020 By Nancy Crotti

A pair of studies of Abbott’s Xience drug-eluting stent showed no difference between shorter courses of treatment with dual antiplatelet therapy (DAPT) compared with 12 months of DAPT following implantation of the XIENCE drug-eluting stent (DES) in patients who are at a high risk of bleeding. Abbott presented the late-breaking data today at TCT Connect, the […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Implants, Stents Tagged With: abbott, TCT 2020

Abbott’s FreeStyle Libre 3 receives CE Mark

September 28, 2020 By Chris Newmarker

Abbott FreeStyle Libre 3 sensor pennies CGM diabetes

Abbott (NYSE:ABT) has won the CE Mark in the European Union for its next-generation FreeStyle Libre 3 continuous glucose monitoring system. Officials at Abbott boast that the Libre 3 technology includes a super small, thin sensor. It’s the size of two U.S. pennies stacked together and able to accurately provide real-time glucose readings over 14 days […]

Filed Under: Business/Financial News, Diabetes, Diagnostics, Featured, Regulatory/Compliance Tagged With: abbott, Abbott Laboratories

Abbott wins Medicare reimbursement for FreeStyle Libre 2

September 1, 2020 By Sean Whooley

Abbott logo updated

Abbott (NYSE:ABT) announced today that its next-generation FreeStyle Libre 2 iCGM is now available to Medicare patients. The integrated continuous glucose monitoring (iCGM) system met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS), making it accessible to all Medicare patients with diabetes who meet the […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: abbott, Centers for Medicare and Medicaid Services (CMS)

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Interim pages omitted …
  • Go to page 10
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS